Treatment with levodopa and risk for malignant melanoma
Identifieur interne : 003A35 ( Main/Merge ); précédent : 003A34; suivant : 003A36Treatment with levodopa and risk for malignant melanoma
Auteurs : J Rgen H. Olsen [Danemark] ; Karina Tangerud [Danemark] ; Lene Wermuth [Danemark] ; Kirsten Frederiksen [Danemark] ; S Ren Friis [Danemark]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-07-15.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Case-Control Studies, Female, Follow-Up Studies, Humans, Incidence, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Melanoma (complications), Melanoma (epidemiology), Odds Ratio, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson's disease, Retrospective Studies, Risk, levodopa treatment, malignant melanoma, nonmelanoma skin cancer.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Melanoma, Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Melanoma, Parkinson Disease.
- Case-Control Studies, Female, Follow-Up Studies, Humans, Incidence, Male, Odds Ratio, Retrospective Studies, Risk.
Abstract
A large follow‐up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case–control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8–1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21397
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001C95
- to stream Istex, to step Curation: 001C95
- to stream Istex, to step Checkpoint: 001621
- to stream PubMed, to step Corpus: 002684
- to stream PubMed, to step Curation: 002684
- to stream PubMed, to step Checkpoint: 002495
- to stream Ncbi, to step Merge: 001C55
- to stream Ncbi, to step Curation: 001C55
- to stream Ncbi, to step Checkpoint: 001C55
Links to Exploration step
ISTEX:D12E7854CF05320F03B3DC7AA5FC409DF67669C8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with levodopa and risk for malignant melanoma</title>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name>
</author>
<author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name>
</author>
<author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name>
</author>
<author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D12E7854CF05320F03B3DC7AA5FC409DF67669C8</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21397</idno>
<idno type="url">https://api.istex.fr/document/D12E7854CF05320F03B3DC7AA5FC409DF67669C8/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001C95</idno>
<idno type="wicri:Area/Istex/Curation">001C95</idno>
<idno type="wicri:Area/Istex/Checkpoint">001621</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Olsen J:treatment:with:levodopa</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17534943</idno>
<idno type="wicri:Area/PubMed/Corpus">002684</idno>
<idno type="wicri:Area/PubMed/Curation">002684</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002495</idno>
<idno type="wicri:Area/Ncbi/Merge">001C55</idno>
<idno type="wicri:Area/Ncbi/Curation">001C55</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001C55</idno>
<idno type="wicri:Area/Main/Merge">003A35</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment with levodopa and risk for malignant melanoma</title>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Neurology, Sønderborg Hospital</wicri:regionArea>
<wicri:noRegion>Sønderborg Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-07-15">2007-07-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1252">1252</biblScope>
<biblScope unit="page" to="1257">1257</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D12E7854CF05320F03B3DC7AA5FC409DF67669C8</idno>
<idno type="DOI">10.1002/mds.21397</idno>
<idno type="ArticleID">MDS21397</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Case-Control Studies</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Melanoma (complications)</term>
<term>Melanoma (epidemiology)</term>
<term>Odds Ratio</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson's disease</term>
<term>Retrospective Studies</term>
<term>Risk</term>
<term>levodopa treatment</term>
<term>malignant melanoma</term>
<term>nonmelanoma skin cancer</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Melanoma</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Melanoma</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Case-Control Studies</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Odds Ratio</term>
<term>Retrospective Studies</term>
<term>Risk</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A large follow‐up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case–control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8–1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.21397"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with levodopa and risk for malignant melanoma</title>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name>
</author>
<author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name>
</author>
<author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name>
</author>
<author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D12E7854CF05320F03B3DC7AA5FC409DF67669C8</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21397</idno>
<idno type="url">https://api.istex.fr/document/D12E7854CF05320F03B3DC7AA5FC409DF67669C8/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001C95</idno>
<idno type="wicri:Area/Istex/Curation">001C95</idno>
<idno type="wicri:Area/Istex/Checkpoint">001621</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Olsen J:treatment:with:levodopa</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment with levodopa and risk for malignant melanoma</title>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Neurology, Sønderborg Hospital</wicri:regionArea>
<wicri:noRegion>Sønderborg Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
<affiliation wicri:level="3"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-07-15">2007-07-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1252">1252</biblScope>
<biblScope unit="page" to="1257">1257</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D12E7854CF05320F03B3DC7AA5FC409DF67669C8</idno>
<idno type="DOI">10.1002/mds.21397</idno>
<idno type="ArticleID">MDS21397</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>levodopa treatment</term>
<term>malignant melanoma</term>
<term>nonmelanoma skin cancer</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A large follow‐up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case–control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8–1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa. © 2007 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with levodopa and risk for malignant melanoma.</title>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H" last="Olsen">J Rgen H. Olsen</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. jorgen@cancer.dk</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name>
</author>
<author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name>
</author>
<author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="doi">10.1002/mds.21397</idno>
<idno type="RBID">pubmed:17534943</idno>
<idno type="pmid">17534943</idno>
<idno type="wicri:Area/PubMed/Corpus">002684</idno>
<idno type="wicri:Area/PubMed/Curation">002684</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002495</idno>
<idno type="wicri:Area/Ncbi/Merge">001C55</idno>
<idno type="wicri:Area/Ncbi/Curation">001C55</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001C55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment with levodopa and risk for malignant melanoma.</title>
<author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H" last="Olsen">J Rgen H. Olsen</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. jorgen@cancer.dk</nlm:affiliation>
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea>
<placeName><settlement type="city">Copenhague</settlement>
<region type="région" nuts="2">Hovedstaden</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tangerud, Karina" sort="Tangerud, Karina" uniqKey="Tangerud K" first="Karina" last="Tangerud">Karina Tangerud</name>
</author>
<author><name sortKey="Wermuth, Lene" sort="Wermuth, Lene" uniqKey="Wermuth L" first="Lene" last="Wermuth">Lene Wermuth</name>
</author>
<author><name sortKey="Frederiksen, Kirsten" sort="Frederiksen, Kirsten" uniqKey="Frederiksen K" first="Kirsten" last="Frederiksen">Kirsten Frederiksen</name>
</author>
<author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Case-Control Studies</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Melanoma (complications)</term>
<term>Melanoma (epidemiology)</term>
<term>Odds Ratio</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Retrospective Studies</term>
<term>Risk</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Melanoma</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Melanoma</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Case-Control Studies</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Odds Ratio</term>
<term>Retrospective Studies</term>
<term>Risk</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A large follow-up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case-control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8-1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A35 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003A35 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:D12E7854CF05320F03B3DC7AA5FC409DF67669C8 |texte= Treatment with levodopa and risk for malignant melanoma }}
This area was generated with Dilib version V0.6.23. |